[go: up one dir, main page]

AU2001258659A1 - Improved methods of transfection - Google Patents

Improved methods of transfection

Info

Publication number
AU2001258659A1
AU2001258659A1 AU2001258659A AU5865901A AU2001258659A1 AU 2001258659 A1 AU2001258659 A1 AU 2001258659A1 AU 2001258659 A AU2001258659 A AU 2001258659A AU 5865901 A AU5865901 A AU 5865901A AU 2001258659 A1 AU2001258659 A1 AU 2001258659A1
Authority
AU
Australia
Prior art keywords
transfection
improved methods
methods
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001258659A
Inventor
Stephen Lewis Hart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ICH Productions Ltd
Original Assignee
ICH Productions Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0013090A external-priority patent/GB0013090D0/en
Priority claimed from GB0013089A external-priority patent/GB0013089D0/en
Application filed by ICH Productions Ltd filed Critical ICH Productions Ltd
Publication of AU2001258659A1 publication Critical patent/AU2001258659A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2001258659A 2000-05-30 2001-05-30 Improved methods of transfection Abandoned AU2001258659A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0013090A GB0013090D0 (en) 2000-05-30 2000-05-30 Intergrin-targetting vectors having enhanced transfection activity
GB0013089A GB0013089D0 (en) 2000-05-30 2000-05-30 Improved methods of transfection
GB0013090.6 2000-05-30
GB0013089.8 2000-05-30
US28741001P 2001-05-01 2001-05-01
US60/287,410 2001-05-01
PCT/GB2001/002396 WO2001092543A2 (en) 2000-05-30 2001-05-30 Improved methods of transfection

Publications (1)

Publication Number Publication Date
AU2001258659A1 true AU2001258659A1 (en) 2001-12-11

Family

ID=27255741

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001258659A Abandoned AU2001258659A1 (en) 2000-05-30 2001-05-30 Improved methods of transfection
AU2001260467A Abandoned AU2001260467A1 (en) 2000-05-30 2001-05-30 Integrin-targeting vectors having enhanced transfection activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001260467A Abandoned AU2001260467A1 (en) 2000-05-30 2001-05-30 Integrin-targeting vectors having enhanced transfection activity

Country Status (5)

Country Link
EP (1) EP1285081A2 (en)
JP (1) JP2003534804A (en)
AU (2) AU2001258659A1 (en)
CA (1) CA2410419A1 (en)
WO (2) WO2001092543A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268668B2 (en) 2003-05-09 2007-09-11 American Express Travel Related Services Company, Inc. Systems and methods for managing multiple accounts on a RF transaction instrument
KR100904954B1 (en) * 2001-05-30 2009-06-26 더 스크립스 리서치 인스티튜트 Delivery System for Nucleic Acids
AR037756A1 (en) * 2001-12-17 2004-12-01 Bayer Corp ANTIBODY INHIBITING THE ACTIVITY OF THE PRECURSOR CELL FACTOR AND ITS USE FOR THE TREATMENT OF ASTHMA.
FR2860236B1 (en) * 2003-09-25 2006-01-06 Theraptosis PEPTIDES HAVING PARTICULARLY ANTI-ANGIOGENIC ACTIVITY AND THERAPEUTIC APPLICATIONS THEREOF
ES2633453T3 (en) 2008-01-24 2017-09-21 Esperance Pharmaceuticals Constructs of fusion of lithic domains and methods of preparation and use thereof
EP3468613A1 (en) 2016-06-09 2019-04-17 CureVac AG Hybrid carriers for nucleic acid cargo
EP3468609A1 (en) * 2016-06-09 2019-04-17 CureVac AG Cationic carriers for nucleic acid delivery

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0494175A4 (en) * 1989-09-27 1993-05-05 Athena Neurosciences, Inc. Compositions for cell adhesion inhibition and methods of use
EP0632722A4 (en) * 1992-03-20 1997-07-30 Baylor College Medicine A dna transporter system and method of use.
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
AUPM747694A0 (en) * 1994-08-16 1994-09-08 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids and peptides
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
WO1997033605A1 (en) * 1996-03-15 1997-09-18 Yale University Human occludin, its uses and enhancement of drug absorption using occludin inhibitors
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
GB9711115D0 (en) * 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
AU9692198A (en) * 1997-10-10 1999-05-03 Kevin J. Donahue Gene delivery compositions and methods
WO1999040214A2 (en) * 1998-02-09 1999-08-12 Genzyme Corporation Nucleic acid delivery vehicles
US6448390B1 (en) * 1998-05-20 2002-09-10 The University Of Tennessee Research Corporation Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy
AU4417000A (en) * 1999-04-15 2000-11-02 Glaxo Group Limited Novel pharmaceutical composition suitable for gene therapy

Also Published As

Publication number Publication date
WO2001092542A2 (en) 2001-12-06
EP1285081A2 (en) 2003-02-26
JP2003534804A (en) 2003-11-25
CA2410419A1 (en) 2001-12-06
AU2001260467A1 (en) 2001-12-11
WO2001092542A3 (en) 2003-05-30
WO2001092543A3 (en) 2002-09-12
WO2001092542A8 (en) 2003-12-24
WO2001092543A2 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
AU3867400A (en) Methods of using bioelastomers
AU2001291859A1 (en) Use of copolycarbonates
AU2001227916A1 (en) Earplug
AU2001240115A1 (en) Method for the preparation of tetrahydrobenzothiepines
AU2001294912A1 (en) Hydroxyesters of 7-desmethylrapamycin
AU2557500A (en) Methods of making compounds
AU2001253418A1 (en) Compounds and methods
AU2001259702A1 (en) Tissue regrafting
AU2001275007A1 (en) Methods of testing materials
AU2001257297A1 (en) Method of authenticating user
AU2001243394A1 (en) Compounds and methods
AU2001276874A1 (en) Continuous preparation of polycarbonate
AU2002228932A1 (en) Maturation of dendritic cells
AU2001258659A1 (en) Improved methods of transfection
AU2001266176A1 (en) Methods
AUPQ904100A0 (en) Method of encryption
AU2001290147A1 (en) Transfection using plasmid preparations
AU2001245950A1 (en) Preparation of deoxynucleosides
AU2001250536A1 (en) Methods
AUPR069500A0 (en) Tissue modification
AU2001289075A1 (en) Enhanced transfection system
HK1050548A (en) Improved methods of transfection
AU2001269061A1 (en) Transfection method
AU2001253560A1 (en) Methods of treatment
AU2001249776A1 (en) Method of polycarbonate preparation